CLINUVEL PHARMACEUTICALS LIMITED (CUV)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CUV - CLINUVEL PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 0.02
Index: ASX300 | ALL-ORDS

Clinuvel is a biopharmaceutical company that develops and commercialises treatments for patients with genetic, metabolic and life threatening disorders. The company was founded and listed in 2001.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$15.29

18 Apr
2024

0.140

OPEN

$15.00

0.92%

HIGH

$15.30

62,525

LOW

$14.94

TARGET
$18.75 22.6% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . ARX . AVH . BIO . BOT . CSL . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
CUV: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx N/A 69.5 xxx
DPS (cps) xxx N/A 6.3 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 20.7 xxx
Dividend Yield xxx N/A 0.4% xxx
Div Pay Ratio(%) xxx N/A 9.1% xxx

Dividend yield today if purchased 3 years ago: 0.17%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.35

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 06/09 - ex-div 4c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx61.9
DPS All xxxxxxxxxxxxxxx5.0
Sales/Revenue xxxxxxxxxxxxxxx78.3 M
Book Value Per Share xxxxxxxxxxxxxxx333.2
Net Operating Cash Flow xxxxxxxxxxxxxxx36.9 M
Net Profit Margin xxxxxxxxxxxxxxx39.08 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx21.09 %
Return on Invested Capital xxxxxxxxxxxxxxx20.97 %
Return on Assets xxxxxxxxxxxxxxx18.04 %
Return on Equity xxxxxxxxxxxxxxx21.09 %
Return on Total Capital xxxxxxxxxxxxxxx27.98 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx33.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx0 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx157 M
Price To Book Value xxxxxxxxxxxxxxx5.37

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx1.0 M
Capex % of Sales xxxxxxxxxxxxxxx1.31 %
Cost of Goods Sold xxxxxxxxxxxxxxx28 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx10 M
Research & Development xxxxxxxxxxxxxxx1 M
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.7

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

26/02/2024

3

Hold

$18.00

17.72%

Operating expenses in the 1H for Clinuvel Pharmaceuticals materially outpaced revenue, resulting in an underlying earnings (EBIT) decline of -13%, explains Ord Minnett.

Disappointing sales growth of 4% constant currency versus 19% in the previous corresponding period was partly due to timing issues.

Operating expenses grew due to a 10% rise in employees and a new commercial office facility, explains the analyst.

The broker feels demand for Scenesse is slowing more than anticipated though the valuation impact is largely offset by the time value of money, and the $18 target and Accumulate rating are maintained.

FORECAST
Ord Minnett forecasts a full year FY24 dividend of 7.00 cents and EPS of 71.20 cents.
Ord Minnett forecasts a full year FY25 dividend of 8.00 cents and EPS of 82.40 cents.

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

CUV STOCK CHART

FNArena News on CUV

1
The Short Report – 21 Mar 2024

Mar 21 2024 - Weekly Reports
2
Weekly Ratings, Targets, Forecast Changes – 15-03-24

Mar 18 2024 - Weekly Reports
3
Australian Broker Call *Extra* Edition – Mar 12, 2024

Mar 12 2024 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Mar 06, 2024

Mar 06 2024 - Daily Market Reports
5
Weekly Ratings, Targets, Forecast Changes – 23-02-24

Feb 26 2024 - Weekly Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Race Oncology

Apr 09 2024 - Small Caps
2
The Power Of New Weight-Loss Drugs

Apr 03 2024 - International
3
Dr Boreham’s Crucible: Neuren Pharmaceuticals

Mar 11 2024 - Small Caps
4
Spotlight On ASX-Listed Cannabis Companies

Jan 31 2024 - Small Caps
5
Transformational Trial Results For Neuren Pharmaceuticals

Dec 20 2023 - Small Caps
6
Dr Boreham’s Crucible: Imugene

Dec 11 2023 - Small Caps
7
Dr Boreham’s Crucible: PYC Therapeutics

Nov 22 2023 - Small Caps
8
Dr Boreham’s Crucible: Paradigm Biopharmaceuticals

Nov 06 2023 - Small Caps
9
Dr Boreham’s Crucible: Argenica Therapeutics

Sep 28 2023 - Small Caps
10
Dr Boreham’s Crucible: Cleo Diagnostics

Aug 30 2023 - Small Caps